MedTrace Logo

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

NCT02632747 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-07-24

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Obesity

Interventions

DRUG

Empagliflozin

Empagliflozin will be taken once daily

DRUG

Placebo (matching empagliflozin)

Placebo will be taken once daily

DRUG

ramipril

Ramipril will be taken once or twice daily

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-10
Primary Completion
2017-12-19
Completion
2019-07-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02632747 on ClinicalTrials.gov